Articles related to RESEARCH & CLINICAL TRIALS

Phase 2a clinical trials demonstrate benfotiamine’s ability to enhance synaptic activity while maintaining an excellent safety profile, even at doses exceeding normal thiamine blood levels.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.

In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.

Weekly semaglutide administration achieved a 13.7% weight reduction while demonstrating significant improvements in knee osteoarthritis pain, potentially offering a new therapeutic approach for this challenging patient population.